- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06208683
The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students
January 5, 2024 updated by: Sinovac Biotech Co., Ltd
The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine Administrated Alone and Concomitantly With a Quadrivalent Inactivated Influenza Vaccine in Junior High School Students
This study is a randomized, controlled, open-label phase Ⅳ clinical trial of a live attenuated mumps vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
The purpose of this study is to evaluate the immunogenicity and safety of the booster doses of a mumps vaccine administrated alone and concomitantly with a quadrivalent inactivated influenza vaccine in healthy junior high school students.
And the cross-neutralization of mumps vaccine immune serum and mumps virus strains
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
This study is an open-lable, randomised, controlled phase Ⅳ clinical trial in healthy junior high school students to the immunogenicity and safety of the booster doses of a mumps vaccine (MV) administrated alone and concomitantly with a quadrivalent influenza vaccine (QIV) in healthy junior high school students.
The experimental vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
A total of 400 healthy students will be enrolled, including 300 students who have received one dose of mumps-containing vaccine (MCV) before vaccination, and 100 students who have received two doses of mumps-containing vaccine before vaccination.
300 students with a history of 1 dose of MCV will be randomly divided into 3 groups in a ratio of 1:1:1, and will receive 1 dose of MV alone, 1 dose of QIV alone, or 1 dose of MV and 1 dose of QIV simultaneously.
Students with a history of 2 doses of MCV received 1 dose of MV alone.
Blood samples were collected before and 30 days after vaccination.
Pre-vaccination blood samples were used to detect antibody levels of measles, mumps, influenza and varicella, and post-vaccination blood samples were used to detect mumps antibodies and/or influenza antibodies corresponding to the vaccination.
Study Type
Interventional
Enrollment (Actual)
400
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shaanxi
-
Xianyang, Shaanxi, China, 712099
- Qindu Distric Center for Disease Prevention and Control
-
Xianyang, Shaanxi, China, 713199
- Xingping Center for Disease Prevention and Control
-
Yulin, Shaanxi, China, 719054
- Yuyang Distict Center for Disease Prevention and Control
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy junior high school students;
- subjects and/or guardians who can understand and voluntarily sign the informed consent form (For subjects aged 8-17 years, both subjects and guardians need to sign the informed consent form)
- Provision of valid identification.;
- History of 1 or 2 doses of mumps-containing vaccine;
Exclusion Criteria:
- History of mumps or have completed 3 doses of mumps-containing vaccine;
- Receipt of the current seasonal influenza vaccine (except subjects in Arm 4)
- History of asthma or allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea,and angioedema;
- Congenital malformations or developmental disorders, genetic defects, severe malnutrition;
- Autoimmune disease (such as systemic lupus erythematosus) or a state of immunodeficiency / immunosuppression (such as AIDS, after organ transplantation);
- Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc.;
- Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
- Thyroid disease or history of thyroidectomy, asplenia, functional asplenia, any condition resulting in asplenia or splenectomy;
- Abnormal coagulation function diagnosed by a doctor (such as coagulation factor deficiency, coagulation disease, platelet abnormality) or obvious bruising or coagulation disorder;
- Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, topical corticosteroid therapy for acute uncomplicated dermatitis) within the past 6 months;
- Receipt of blood products in the past 3 months;
- Receipt of other investigational drugs in the past 30 days;
- Receipt of attenuated live vaccines in the past 28 days;
- Receipt of inactivated or subunit vaccines in the past 7 days;
- Onset of various acute or chronic diseases within 7 days prior to the study;
- Axillary temperature >37.0°C;
- Participation in other clinical trials before enrollment and during the follow-up period, or a plan to participate in other clinical trials within 3 months.
- Any other factors that are unsuitable for participating in this clinical trial according to the investigator's judgment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1MCV: MV
100 students with a history of 1 dose of MCV will receive 1 dose of MV.
|
0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus
|
Experimental: 1MCV: QIV
100 students with a history of 1 dose of MCV will receive 1 dose of QIV.
|
0.5mL per dose, containing 4 strains of influenza virus recommended by the WHO, 15ug of each strain.
|
Experimental: 1MCV: MV +QIV
100 students with a history of 1 dose of MCV will receive 1 dose of MV and 1 dose of QIV simultaneously.
|
0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus
0.5mL per dose, containing 4 strains of influenza virus recommended by the WHO, 15ug of each strain.
|
Experimental: 2MCV: MV
100 students with a history of 2 dose of MCV will receive 1 dose of MV.
|
0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric mean concentrations (GMCs) of mumps antibody
Time Frame: 30 days after the vaccination of MV
|
GMC s of mumps antibody 30 days after the vaccination of MV
|
30 days after the vaccination of MV
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric mean increases (GMIs) of mumps antibody
Time Frame: 30 days after the vaccination of MV
|
Geometric mean increases (GMIs) of mumps antibody 30 days after the vaccination of MV
|
30 days after the vaccination of MV
|
Seroconversion rate of mumps antibody
Time Frame: 30 days after the vaccination of MV
|
Seroconversion rate of mumps antibody 30 days after the vaccination of MV
|
30 days after the vaccination of MV
|
Seropositivity rate of mumps antibody
Time Frame: 30 days after the vaccination of MV
|
Seropositivity rate of mumps antibody 30 days after the vaccination of MV
|
30 days after the vaccination of MV
|
Geometric mean titers (GMTs) of influenza antibody
Time Frame: 30 days after the vaccination of QIV
|
Geometric mean titers (GMTs) of influenza antibody 30 days after the vaccination of QIV
|
30 days after the vaccination of QIV
|
Geometric mean increases (GMIs) of influenza antibody
Time Frame: 30 days after the vaccination of QIV
|
Geometric mean increases (GMIs) of influenza antibody 30 days after the vaccination of QIV
|
30 days after the vaccination of QIV
|
Seroconversion rate of influenza antibody
Time Frame: 30 days after the vaccination of QIV
|
Seroconversion rate of influenza antibody 30 days after the vaccination of QIV
|
30 days after the vaccination of QIV
|
Seropositivity rate of influenza antibody
Time Frame: 30 days after the vaccination of QIV
|
Seropositivity rate of influenza antibody 30 days after the vaccination of QIV
|
30 days after the vaccination of QIV
|
Geometric mean concentrations (GMCs) of mumps antibody 30 days after the simultaneous vaccination of MV and QIV
Time Frame: 30 days after the simultaneous vaccination of MV and QIV
|
Geometric mean concentrations (GMCs) of mumps antibody
|
30 days after the simultaneous vaccination of MV and QIV
|
Geometric mean titers (GMTs) of influenza antibody 30 days after the simultaneous vaccination of MV and QIV
Time Frame: 30 days after the simultaneous vaccination of MV and QIV
|
Geometric mean titers (GMTs) of influenza antibody
|
30 days after the simultaneous vaccination of MV and QIV
|
Geometric mean increases (GMIs) of mumps antibody and influenza antibody
Time Frame: 30 days after the simultaneous vaccination of MV and QIV
|
Geometric mean increases (GMIs) of mumps antibody and influenza antibody 30 days after the simultaneous vaccination of MV and QIV
|
30 days after the simultaneous vaccination of MV and QIV
|
Seroconversion rate of mumps antibody and influenza antibody
Time Frame: 30 days after the simultaneous vaccination of MV and QIV
|
Seroconversion rate of mumps antibody and influenza antibody 30 days after the simultaneous vaccination of MV and QIV
|
30 days after the simultaneous vaccination of MV and QIV
|
Seropositivity rate of mumps antibody and influenza antibody
Time Frame: 30 days after the simultaneous vaccination of MV and QIV
|
Seropositivity rate of mumps antibody and influenza antibody 30 days after the simultaneous vaccination of MV and QIV
|
30 days after the simultaneous vaccination of MV and QIV
|
The incidence of adverse reactions 0-7 days after vaccination
Time Frame: 0-7 days after vaccination
|
The incidence of adverse reactions 0-7 days after vaccination
|
0-7 days after vaccination
|
The incidence of adverse reactions 0-14 days after vaccination
Time Frame: 0-14 days after vaccination
|
The incidence of adverse reactions 0-14 days after vaccination
|
0-14 days after vaccination
|
The incidence of adverse reactions 0-30 days after vaccination
Time Frame: 0-30 days after vaccination
|
The incidence of adverse reactions 0-30 days after vaccination
|
0-30 days after vaccination
|
Geometric mean concentrations (GMCs) of measles antibody before vaccination
Time Frame: before vaccination
|
Geometric mean concentrations (GMCs) of measles antibody before vaccination
|
before vaccination
|
Geometric mean concentrations (GMCs) of rubella antibody before vaccination
Time Frame: before vaccination
|
Geometric mean concentrations (GMCs) of rubella antibody before vaccination
|
before vaccination
|
Geometric mean titers (GMTs) of varicella-zostor antibody before vaccination
Time Frame: before vaccination
|
Geometric mean titers (GMTs) of varicella-zostor antibody before vaccination
|
before vaccination
|
Geometric mean concentrations (GMCs) of mumps antibody before vaccination
Time Frame: before vaccination
|
Geometric mean concentrations (GMCs) of mumps antibody before vaccination
|
before vaccination
|
Geometric mean titers (GMTs) of influenza antibody before vaccination
Time Frame: before vaccination
|
Geometric mean titers (GMTs) of influenza antibody before vaccination
|
before vaccination
|
Seropositivity rate of measles antibody before vaccination
Time Frame: before vaccination
|
Seropositivity rate of measles antibody before vaccination
|
before vaccination
|
Seropositivity rate of rubella antibody before vaccination
Time Frame: before vaccination
|
Seropositivity rate of rubella antibody before vaccination
|
before vaccination
|
Seropositivity rate of varicella-zostor antibody before vaccination
Time Frame: before vaccination
|
Seropositivity rate of varicella-zostor antibody before vaccination
|
before vaccination
|
Seropositivity rate of mumps antibody before vaccination
Time Frame: before vaccination
|
Seropositivity rate of mumps antibody before vaccination
|
before vaccination
|
Seropositivity rate of influenza antibody before vaccination
Time Frame: before vaccination
|
Seropositivity rate of influenza antibody before vaccination
|
before vaccination
|
Cross-neutralizing antibody titer of mumps vaccine
Time Frame: 30 days after the vaccination of MV alone or simultaneously with QIV
|
Cross-neutralizing antibody titer of mumps vaccine against different genotypes of mumps virus
|
30 days after the vaccination of MV alone or simultaneously with QIV
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Weijun Hu, Master, Shaanxi Provincial Center for Disease Prevention and Control
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 4, 2023
Primary Completion (Estimated)
February 2, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
November 23, 2023
First Submitted That Met QC Criteria
January 5, 2024
First Posted (Actual)
January 17, 2024
Study Record Updates
Last Update Posted (Actual)
January 17, 2024
Last Update Submitted That Met QC Criteria
January 5, 2024
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Stomatognathic Diseases
- Mouth Diseases
- Paramyxoviridae Infections
- Mononegavirales Infections
- Orthomyxoviridae Infections
- Salivary Gland Diseases
- Rubulavirus Infections
- Parotitis
- Parotid Diseases
- Influenza, Human
- Mumps
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- PRO-MUM-MA4001-SN
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mumps
-
GlaxoSmithKlineCompletedMeasles; Mumps; Rubella | Measles-Mumps-Rubella VaccineUnited States, Finland, Taiwan, Estonia, Puerto Rico
-
Institute of Medical Biology, Chinese Academy of...Hubei Provincial Center for Disease Control and PreventionActive, not recruitingEpidemic Parotitis, MumpsChina
-
Institute of Medical Biology, Chinese Academy of...Hubei Provincial Center for Disease Control and PreventionActive, not recruitingEpidemic Parotitis,MumpsChina
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | Measles-Mumps-Rubella VaccineFinland, Thailand, United States, Spain, Czechia, Puerto Rico, Malaysia
-
GlaxoSmithKlineCompletedMeasles-Mumps-RubellaTaiwan, United States, Korea, Republic of
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | Measles-Mumps-Rubella VaccineUnited States, Puerto Rico
-
GlaxoSmithKlineActive, not recruitingMeasles; Mumps; Rubella; ChickenpoxUnited States, Taiwan, Spain, Argentina, Turkey, Colombia, Puerto Rico, Latvia, Chile
-
Merck Sharp & Dohme LLCCompletedMeasles | Rubella | Mumps | Varicella
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedMeasles | Rubella | Mumps | Varicella
Clinical Trials on Mumps vaccine, Live (MV)
-
Sinovac Research and Development Co., Ltd.Completed
-
Sinovac (Dalian) Vaccine Technology Co., Ltd.Completed
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | VaricellaBelgium, Germany, Netherlands
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | VaricellaGermany
-
Sichuan Center for Disease Control and PreventionChina National Biotec Group Company LimitedUnknown
-
Merck Sharp & Dohme LLCCompleted
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | VaricellaFinland, Germany, Poland, Greece
-
Sinovac (Dalian) Vaccine Technology Co., Ltd.Completed
-
Shanghai Institute Of Biological ProductsCompleted
-
Merck Sharp & Dohme LLCCompleted